Literature DB >> 7793493

Classification and treatment of local septic complications in acute pancreatitis.

T J Howard1, E A Wiebke, G Mogavero, K Kopecky, J C Baer, S Sherman, R H Hawes, G A Lehman, R J Goulet, J A Madura.   

Abstract

BACKGROUND: An international symposium on acute pancreatitis recently developed a clinical classification system for severe acute pancreatitis that classifies all local septic complications into three groups: infected necrosis (IN), sterile necrosis (SN), and pancreatic abscess (PA). Despite the appeal of having three distinct, well-defined labels for this complex process, the clinical utility of this schema has yet to be determined. The purpose of this study was to investigate the prognostic and therapeutic utility of applying this clinical classification system to a large group of surgical patients with local septic complication from acute pancreatitis. PATIENTS AND METHODS: We reviewed the cases of 62 patients with complicated pancreatitis, classifying them into IN (n = 20), SN (n = 14), or PA (n = 28) groups. Ranson's score, APACHE II score, and computed tomography grading were calculated within the first 48 hours of admission. Information on patient demographics, etiology of pancreatitis, operative procedures, timing of intervention, bacteriology, blood loss, intensive care unit days, ventilator days, and morbidity and mortality were also accrued and analyzed.
RESULTS: Despite similar demographics and etiology of pancreatitis, patients with necrosis, both IN and SN, were more critically ill than were patients with PA (APACHE II score > 15, 21% versus 0%, respectively), required earlier operative intervention (mean 14 days versus 29 days, P = 0.02), required necrosectomy with drainage (65% versus 4%, P < 0.001) rather than simple drainage (3% versus 86%, P < 0.001), more reoperations (2.3 versus 1.1, P < 0.05), and had a significantly higher mortality rate (35% versus 4%, P < 0.05). In addition, patients with IN required significantly more hospital days, ventilator days, and blood transfusions than either patients with SN or PA (P < 0.05).
CONCLUSIONS: We conclude that this classification system allows for the stratification of patients into three distinct groups--infected necrosis, sterile necrosis, and pancreatic abscess--and has both therapeutic and prognostic usefulness.

Entities:  

Mesh:

Year:  1995        PMID: 7793493     DOI: 10.1016/s0002-9610(99)80250-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Using the polymerase chain reaction coupled with denaturing gradient gel electrophoresis to investigate the association between bacterial translocation and systemic inflammatory response syndrome in predicted acute severe pancreatitis.

Authors:  Callum B Pearce; Vitaly Zinkevich; Iwona Beech; Viera Funjika; Ana Garcia Ruiz; Afraa Aladawi; Hamish D Duncan
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Mortality from acute pancreatitis. Late septic deaths can be avoided but some early deaths still occur.

Authors:  A Lowham; J Lavelle; T Leese
Journal:  Int J Pancreatol       Date:  1999-04

3.  Analysis of the delayed approach to the management of infected pancreatic necrosis.

Authors:  Nilesh Doctor; Sujith Philip; Vidhyachandra Gandhi; Maharra Hussain; Savio G Barreto
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

4.  Comparative Analysis of Early Clinical Features and Complications of Different Types of Acute Pancreatitis.

Authors:  Hongsheng Wu; Keqiang Ma; Biling Liao; Tengfei Ji; Shengmin Zhang; Tiansheng Cao
Journal:  Oxid Med Cell Longev       Date:  2022-06-25       Impact factor: 7.310

5.  Declining morbidity and mortality rates in the surgical management of pancreatic necrosis.

Authors:  Thomas J Howard; Jay B Patel; Nicholas Zyromski; Kumar Sandrasegaran; Jian Yu; Atilla Nakeeb; Henry A Pitt; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2007-01       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.